Peak Asset Management LLC lifted its stake in shares of Merck & Co. (NYSE:MRK) by 14.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 17,855 shares of the company’s stock after acquiring an additional 2,322 shares during the period. Peak Asset Management LLC’s holdings in Merck & Co. were worth $1,005,000 at the end of the most recent reporting period.
Several other institutional investors also recently added to or reduced their stakes in MRK. Santori & Peters Inc. bought a new stake in shares of Merck & Co. in the 4th quarter worth $110,000. Stevens First Principles Investment Advisors lifted its holdings in Merck & Co. by 79.3% during the fourth quarter. Stevens First Principles Investment Advisors now owns 2,080 shares of the company’s stock valued at $117,000 after purchasing an additional 920 shares during the last quarter. WealthTrust Arizona LLC lifted its holdings in Merck & Co. by 103.7% during the fourth quarter. WealthTrust Arizona LLC now owns 2,495 shares of the company’s stock valued at $140,000 after purchasing an additional 1,270 shares during the last quarter. Taylor Hoffman Wealth Management purchased a new stake in Merck & Co. during the fourth quarter valued at about $156,000. Finally, Delpha Capital Management LLC purchased a new stake in Merck & Co. during the fourth quarter valued at about $158,000. Institutional investors own 74.87% of the company’s stock.
MRK has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Merck & Co. from a “hold” rating to a “buy” rating and set a $66.00 price target on the stock in a report on Tuesday, April 17th. Morgan Stanley upgraded shares of Merck & Co. from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $59.80 to $63.00 in a research report on Tuesday, April 17th. Deutsche Bank restated a “hold” rating on shares of Merck & Co. in a research report on Wednesday, April 25th. BMO Capital Markets raised their target price on shares of Merck & Co. from $65.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday, April 26th. Finally, Barclays raised Merck & Co. from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $62.00 to $64.00 in a research note on Thursday, April 5th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $65.87.
Merck & Co. opened at $59.07 on Friday, according to Marketbeat Ratings. Merck & Co. has a one year low of $59.04 and a one year high of $59.65. The stock has a market capitalization of $161.10 billion, a P/E ratio of 14.84, a price-to-earnings-growth ratio of 2.28 and a beta of 0.76. The company has a quick ratio of 1.10, a current ratio of 1.42 and a debt-to-equity ratio of 0.63.
Merck & Co. (NYSE:MRK) last released its quarterly earnings results on Tuesday, May 1st. The company reported $1.05 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.00 by $0.05. The business had revenue of $10.04 billion during the quarter, compared to the consensus estimate of $10.09 billion. Merck & Co. had a return on equity of 30.93% and a net margin of 4.31%. The business’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.88 EPS. sell-side analysts expect that Merck & Co. will post 4.23 EPS for the current year.
Merck & Co. Company Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.